References
- International Study of Asthma and Allergies in Childhood Screening Committee. Worldwide variations in the prevalence of symptoms of asthma. Allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet351, 1225–1232 (1998).
- Brehler R, Luger TA. Atopy: immunodeviation and environment. J. Allergy Clin. Immunol.104, 1128–1130 (1999).
- Muñoz F, Ríos M. Estudio epidemiológico de la patología alérgica de la población general infantil en España. Repercusión socioeconómica. Alergol. Inmunol. Clin.9, 23–35 (1994).
- Campos A, Enguidanos M. Incidencia de asma, rinitis, urticaria y alergia medicamentosa en medio rural y urbano. Projecte Orb-83. Alergol. Inmunol. Clin.8, 89–95 (1993).
- Gaig P, Ferrer M, Muñoz-Lejarazu D et al. Prevalencia de alergia en la población adulta española. Alergol. Inmunol. Clin.19, 68–74 (2004).
- Alergológica: Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España. Sociedad Española de Alergología e Inmunología Clínica y Alergia e Inmunología Abello SA (Ed.). NILO Industria Gráfica, Madrid, Spain 163–183 (1995).
- Jay S, Litt IF, Durant RH. Compliance with therapeutic regimens. J. Adolesc. Health Care5(2), 124–136 (1984).
- Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract.57(7), 573–576 (2003).
- Artés MaT, De Agustín T, Galván J, Heras M. Influencia y valor de las preferencias del paciente en la prescripción médica. Estudio de opinión entre profesionales de la salud. Salud. Rural.24(4), 37–47 (2007).
- Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann. Allergy Asthma Immunol.76, 507–512 (1996).
- Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs52, 20–25 (1996).
- Davies RJ. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin. Drug Invest.16, 413–420 (1998).
- Bousquet J, Gaudano EM, Palma Carlos AG et al. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy54, 562–568 (1999).
- Hurst M, Spencer CM. Ebastine – an update of its use in allergic disorders. Drugs59, 981–1006 (2000).
- Hampel F Jr, Howland W III, Van Bavel J et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol.14, 56–63 (2004).
- Salvà M, Carreño B, Pintos M et al. Phase I, single dose, open-label, randomized, crossover bioequivalence studies of ebastine 10 and 20 mg fast-dissolving tablets in healthy male volunteers. Interasma – EAACI Joint Meeting, Bilbao, Spain 28 November 2004 (Poster OC9).
- Bousquet P, Van Cauwenberge P, Khaltaev N. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy59, 373–387 (2004).
- Haynes RB, Montague P, Oliver T et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Library Reviews3, 1–26 (2000).
- Gil VF, Belda J, Piñero F et al. El incumplimiento en la práctica clínica: toma de decisiones diagnósticas y terapéuticas. Med. Clin. (Barc.)116, 77–86 (2001).
- Roger A, Fortea J, Artés M, Montilla L. Acceptability and preference of the placebo fast dissolving tablet vs placebo regular tablets of ebastine in consumers of oral antihistamines with allergic rhinitis. Pharmaceutical Care (Spain)7, 159 (2005).
- Channer KS, Virjee JP. Effect of size and shape of tablets on their oesophageal transit. J. Clin. Pharmacol.26, 141–146 (1986).
- Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol.50, 375–382 (1998).
Websites
- Strategic Perspectives: Allergic Rhinitis: impact of a blockbuster going bust. Datamonitor www.datamonitor.com/healthcare, DMHC1794 (Published August 2002).